BCL2L1 and melanoma: Additionally, the antitumor activity of SSOs was also demonstrated in vivo in a mouse model of melanoma lung metastases where the systemic administration of Bcl-x SSO using a lipid nanoparticle redirected Bcl-x splicing and led to a significant reduction in tumor burden in treated mice [183].